Delcath axes one-third of staff after FDA rejection

Delcath's ($DCTH) year of disappointment lumbers on as the New York company axes 21 of its 60 employees, looking to cut costs as it figures out just what to do with an FDA-rejected device. Last month, the agency finally closed the door on Melblez, a drug-device combo designed to treat eye cancer that has spread to the liver, which came as little shock to anyone paying attention. The FDA demanded another randomized clinical trial for the combo, likely postponing an approval date by years, and Delcath summarily fired CEO Eamonn Hobbs, appointing two of its executive vice presidents to serve as co-CEOs as it decides how to proceed with the FDA. Story

Suggested Articles

Solid Bio fixed the manufacturing issue that led to a partial clinical hold on its DMD trial, but a full hold remains.

Commissioner Scott Gottlieb has laid out the reasons why he thinks the FDA needs a double-digit budget bump.

GW's cannabis-based epilepsy drug scored a favorable review from FDA staff ahead of an expert panel meeting.